ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

duvelisib

Also written as “Duvelisib”, “IPI-145” and “IPI-145 (duvelisib)”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma · Lymphoma, Follicular · Hematologic Neoplasms · Mycosis Fungoides, led by 3 companies.

Drug pageDuvelisib: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 13, 201326 company-led studies, 2 open or runningNext primary completion: Feb 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
SecuraBioits history only232 open or runningphase 3since Nov 13, 2013Nov 17, 2011Feb 2028phase 3 · NCT06522737
AbbVie20 open or runningphase 1since Oct 21, 2015Oct 21, 2015none ahead
CSPC Pharmaceutical Groupits history only10 open or runningphase 2since Apr 24, 2020Apr 24, 2020none ahead

Also a collaborator on its studies: Infinity Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 21, 2015First study: phase 1 study in LymphomaFirst studyNCT02598570 · 7 enrolled · Japan
  2. Dec 23, 2015Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02640833 · United States

TargetBeta

“PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
gedatolisibrulePfizerphase 39
paxalisibrulekazia-therapeutics-limitedphase 24

Studies

All 2 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02640833Leukemia, Lymphocytic, Chronic, B-Cell · United States1WithdrawnJan 20200
NCT02598570Lymphoma · Japan1CompletedDec 20167

How it is read

Names in the registry

  • “Duvelisib”, 16 entries
  • “IPI-145”, 9 entries
  • “IPI-145 (duvelisib)”, 3 entries
  • “IPI-145, a PI3K Inhibitor”, 1 entry
  • “duvelisib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.